Leerink Partners maintained a Market Perform rating on CVS Health (NYSE:CVS) shares while increasing the price target from ...

In a dramatic turnaround from bankruptcy court less than two years ago, Leerink Partners is now on the offensive and hiring ...

A Wall Street Journal report noted that a prospective deal between Walgreens and New York private-equity firm Sycamore ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...

Drug developer Maze Therapeutics said on Monday it was targeting a valuation of as much as $728.1 million in its initial ...

Securities reiterated its Outperform rating on HCA Healthcare Inc (NYSE:HCA), an $83 billion market cap healthcare provider, ...

Sources told CNBC's David Faber that a private equity firm's prospective deal to acquire Walgreens Boots Alliance is ...

Research analysts at Leerink Partnrs reduced their Q4 2024 earnings per share (EPS) estimates for shares of BridgeBio Pharma ...

SAN FRANCISCO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative ...

Gossamer Bio (GOSS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on January 24. Analyst Joseph ...

Whit Mayo, an analyst from Leerink Partners, reiterated the Buy rating on Elevance Health (ELV – Research Report). The associated price target ...

Vir Biotechnology (NASDAQ:VIR – Get Free Report) had its price objective raised by Leerink Partners from $18.00 to $20.00 in ...